Methods for treating benign prostatic hypertrophy (bph)
AssigneeNew York University
InventorsDavid L. Kleinberg, Sergio Vidal, Weifeng Ruan
Life of this patent
Estimating the term…
Abstract
Therapeutic methods for treating a subject with benign prostatic hypertrophy by inhibition of the activity of insulin-like growth factor-I (IGF-I) to reduce the amount of prostatic hyperplastic tissue in the subject are described herein.
Claims15
A method for treating a subject with benign prostatic hyperplasia (BPH) disease, the method comprising administering a therapeutically effective amount of an inhibitor of IGF-I activity to a subject with BPH, wherein the therapeutically effective amount of the inhibitor of IGF-I activity is administered to reduce the amount of prostatic hyperplastic tissue in the subject and thereby alleviate adverse symptoms of BPH in the subject, wherein the adverse symptoms comprise irritative or obstructive voiding pattern, urinary retention, and/or frequent urination with an increased residual urine volume, thereby treating the subject with BPH.
A method for treating a subject with symptoms comprising irritative or obstructive voiding pattern, urinary retention, and/or frequent urination with an increased residual urine volume, the method comprising administering a therapeutically effective amount of an inhibitor of IGF-I activity to the subject, wherein the therapeutically effective amount of the inhibitor of IGF-I activity is administered to provide symptomatic relief for the subject, thereby treating the subject with symptoms comprising irritative or obstructive voiding pattern, urinary retention, and/or frequent urination with an increased residual urine volume.
A method for treating benign prostatic hyperplasia (BPH) disease in a patient to delay a need for surgical treatment of the patient with BPH, the method comprising administering a therapeutically effective amount of an inhibitor of IGF-I activity to the patient with BPH, wherein the inhibitor of IGF-I activity is a somatostatin analog or a small molecule IGF-I receptor kinase specific inhibitor and the therapeutically effective amount of the inhibitor of IGF-I activity is administered to reduce the amount of prostatic hyperplastic tissue in the patient and thereby delay the need for surgical treatment to reduce the amount of prostatic hyperplastic tissue in the patient.
Dependencies are inferred from the claim text.